2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 655

Non-White Race, Younger Age, and Use of Primary and Gynecologic Care Are Associated with Higher Rates of Cervical Cancer Screening in Systemic Lupus Erythematosus Patients At a Public Hospital
Abstract Number: 1138

Nonpharmacologic and Pharmacologic Therapy Utilization by Primary Care Providers for Hand Osteoarthritis-Comparative Review by Electronic Health Record Data Mining and in-Home Visit Verification
Abstract Number: 1790

Notch Promotes Matrix Metalloproteinase 13 Expression by Inducing Interleukin-6 in Primary Murine Chondrocytes
Abstract Number: 2579

Novel Autoantibodies to 14-3-3 Eta Are Highly Specific for Rheumatoid Arthritis
Abstract Number: 2419

Novel Candidate Genes for Structural Foot Disorders: A Genome-Wide Association Study in an Older Caucasian Population
Abstract Number: 342

Novel Combination Therapy of Existing Repurposed Therapies, Designed by Predictive Software Modeling, Shows Profound Impact On Disease Progression in a Murine Collagen-Induced Arthritis Model
Abstract Number: 2678

Novel Nuclear Export Inhibitors Deplete Autoreactive Plasma Cells and Protect Mice with Lupus-Like Disease From Nephritis
Abstract Number: 33

Novel Targets for Blocking Osteoclast-Mediated Resorption in Inflammatory Disorders
Abstract Number: 2275

NR1H3 (LXR alpha) Gene Polymorphisms Are Associated with Systemic Lupus Erythematosus in Koreans
Abstract Number: 903

NR4A1 Mediates Anti-Inflammatory Effects of Apoptotic Cells
Abstract Number: 213

Nsaids Suppress the Inflammatory Reaction Related to Muscle Soreness but May Delay Recovery
Abstract Number: 533

NT-Probnp and Inflammation in Active Ankylosing Spondylitis Receiving TNF Blockers: Is There a Link?
Abstract Number: 893

Nuclear Factor-κB Activation by Type II Collagen Peptide in Osteoarthritic Chondrocytes: Its Inhibition by Hyaluronan Via CD44
Abstract Number: 898

Nuclear Receptor Related 1 Induces Synovial Hyperplasia Via Transcriptional Regulation of Novel Target Genes
Abstract Number: 1449

Numbers of Splenic Long-Lived Plasma Cells in Autoimmune and Pre-Autoimmune Lupus Mice Are Linked to a Hyper-Responsive Variant of the Thrombopoietin Receptor and Enhanced Megakaryopoiesis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].